134 related articles for article (PubMed ID: 38140926)
21. Prognostic Value of Pretreatment Glasgow Prognostic Score/Modified Glasgow Prognostic Score in Ovarian Cancer: A Systematic Review and Meta-Analysis.
Xu S; Song L; Liu X
Nutr Cancer; 2022; 74(6):1968-1975. PubMed ID: 34549675
[TBL] [Abstract][Full Text] [Related]
22. The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors.
Zhou J; Huang G; Wong WC; Hu DH; Zhu JW; Li R; Zhou H
Front Immunol; 2022; 13():968729. PubMed ID: 35967438
[TBL] [Abstract][Full Text] [Related]
23. A Meta-Analysis of Glasgow Prognostic Score and Modified Glasgow Prognostic Score as Biomarkers for Predicting Survival Outcome in Renal Cell Carcinoma.
Tong T; Guan Y; Xiong H; Wang L; Pang J
Front Oncol; 2020; 10():1541. PubMed ID: 33042799
[No Abstract] [Full Text] [Related]
24. Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment.
Kasahara N; Imai H; Naruse I; Tsukagoshi Y; Kotake M; Sunaga N; Kaira K; Maeno T; Asao T; Hisada T
Thorac Cancer; 2020 Aug; 11(8):2188-2195. PubMed ID: 32495520
[TBL] [Abstract][Full Text] [Related]
25. Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy.
Minichsdorfer C; Gleiss A; Aretin MB; Schmidinger M; Fuereder T
Ann Med; 2022 Dec; 54(1):1339-1349. PubMed ID: 35535695
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
27. Association of the neutrophil to lymphocyte ratio and clinical outcomes in patients with lung cancer receiving immunotherapy: a meta-analysis.
Jin J; Yang L; Liu D; Li W
BMJ Open; 2020 Jun; 10(6):e035031. PubMed ID: 32499266
[TBL] [Abstract][Full Text] [Related]
28. Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.
Imai H; Kishikawa T; Minemura H; Yamada Y; Ibe T; Yamaguchi O; Mouri A; Hamamoto Y; Kanazawa K; Kasai T; Kaira K; Kaburagi T; Minato K; Kobayashi K; Kagamu H
Cancer Med; 2021 Oct; 10(20):6971-6984. PubMed ID: 34414673
[TBL] [Abstract][Full Text] [Related]
29. Glasgow prognostic score predicts prognosis of non-small cell lung cancer: a meta-analysis.
Zhu L; Chen S; Ma S; Zhang S
Springerplus; 2016; 5():439. PubMed ID: 27104127
[TBL] [Abstract][Full Text] [Related]
30. Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Chen X; Meng F; Jiang R
Front Oncol; 2021; 11():746976. PubMed ID: 34900692
[TBL] [Abstract][Full Text] [Related]
31. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
Zhang Z; Yuan F; Chen R; Li Y; Ma J; Yan X; Wang L; Zhang F; Tao H; Guo D; Huang Z; Zhang S; Li X; Zhi X; Ge X; Hu Y; Wang J
Front Immunol; 2020; 11():1173. PubMed ID: 32587591
[No Abstract] [Full Text] [Related]
32. A high Glasgow prognostic score (GPS) or modified Glasgow prognostic score (mGPS) predicts poor prognosis in gynecologic cancers: a systematic review and meta-analysis.
Nie D; Zhang L; Wang C; Guo Q; Mao X
Arch Gynecol Obstet; 2020 Jun; 301(6):1543-1551. PubMed ID: 32409927
[TBL] [Abstract][Full Text] [Related]
33. Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors.
Takamori S; Takada K; Shimokawa M; Matsubara T; Fujishita T; Ito K; Toyozawa R; Yamaguchi M; Okamoto T; Yoneshima Y; Tanaka K; Okamoto I; Tagawa T; Mori M
Lung Cancer; 2021 Feb; 152():27-33. PubMed ID: 33341085
[TBL] [Abstract][Full Text] [Related]
34. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
35. Association between sex and outcomes in patients with non-small-cell lung cancer receiving combination chemoimmunotherapy as a first-line therapy: a systematic review and meta-analysis of randomized clinical trials.
Takada K; Shimokawa M; Mizuki F; Takamori S; Takenaka T; Miura N; Shikada Y; Yoshizumi T
Eur J Med Res; 2022 Aug; 27(1):157. PubMed ID: 35999618
[TBL] [Abstract][Full Text] [Related]
36. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].
Ma SX; Ma N; Han J; He Z; Wang L; Wang Q
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):922-929. PubMed ID: 35385963
[No Abstract] [Full Text] [Related]
37. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
38. Novel evidence for the prognostic impact of β-blockers in solid cancer patients receiving immune checkpoint inhibitors.
Yan X; Liu P; Li D; Hu R; Tao M; Zhu S; Wu W; Yang M; Qu X
Int Immunopharmacol; 2022 Dec; 113(Pt A):109383. PubMed ID: 36330916
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of blood-based PD-L1 analysis in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis.
Cui Q; Li W; Wang D; Wang S; Yu J
World J Surg Oncol; 2023 Oct; 21(1):318. PubMed ID: 37821941
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
